These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38206946)

  • 21. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
    Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
    Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis and biologics in rheumatology: A special situation.
    Handa R; Upadhyaya S; Kapoor S; Jois R; Pandey BD; Bhatnagar AK; Khanna A; Goyal V; Kumar K
    Int J Rheum Dis; 2017 Oct; 20(10):1313-1325. PubMed ID: 28730751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.
    Scrivo R; Sauzullo I; Mengoni F; Riccieri V; Altieri AM; Cantoro L; Vullo V; Mastroianni CM; Valesini G
    Clin Rheumatol; 2016 May; 35(5):1383-8. PubMed ID: 24827875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.
    To KW; Reino JJ; Yoo DH; Tam LS
    Respirology; 2013 Jul; 18(5):765-73. PubMed ID: 23627398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).
    Rath E; Bonelli M; Duftner C; Gruber J; Mandl P; Moazedi-Furst F; Pieringer H; Puchner R; Flick H; Salzer HJF; Weiss G; Winkler S; Skvara H; Moschen A; Hofer H; Feurstein J; Sautner J
    Wien Klin Wochenschr; 2022 Nov; 134(21-22):751-765. PubMed ID: 36036323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan.
    Watanabe A; Matsumoto T; Igari H; Sawa J; Yamaguchi Y; Sakatani M
    Int J Tuberc Lung Dis; 2016 Jan; 20(1):101-8. PubMed ID: 26688535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients.
    Piotto D; Nicacio A; Neto A; Mourão AF; Oliveira-Ramos F; Campanilho-Marques R; Guedes M; Cabral M; Santos MJ; Fonseca JE; Canhão H; Aikawa NE; Oliveira SKF; Ferriani VPL; Pileggi GCS; Magalhães CS; Silva CA; Terreri MT
    Adv Rheumatol; 2022 Jun; 62(1):20. PubMed ID: 35689240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
    Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
    J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
    Liao TL; Lin CH; Chen YM; Chang CL; Chen HH; Chen DY
    PLoS One; 2016; 11(4):e0153217. PubMed ID: 27064275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.